{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T18:48:22Z","timestamp":1772218102336,"version":"3.50.1"},"reference-count":44,"publisher":"Public Library of Science (PLoS)","issue":"3","license":[{"start":{"date-parts":[[2024,3,21]],"date-time":"2024-03-21T00:00:00Z","timestamp":1710979200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"National Institute for Health Research (NIHR) University College London Hospitals Department of Health\u2019s NIHR Biomedical Research Centre"},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000265","name":"UK Medical Research Council","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["[FC011104, FC011233, FC001030, FC001159, FC001827, FC001078, FC001099, FC001169, 206250\/Z\/17\/Z]"],"award-info":[{"award-number":["[FC011104, FC011233, FC001030, FC001159, FC001827, FC001078, FC001099, FC001169, 206250\/Z\/17\/Z]"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Genotype-to-Phenotype National Virology Consortium"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>SARS-CoV-2 variant Omicron rapidly evolved over 2022, causing three waves of infection due to sub-variants BA.1, BA.2 and BA.4\/5. We sought to characterise symptoms and viral loads over the course of COVID-19 infection with these sub-variants in otherwise-healthy, vaccinated, non-hospitalised adults, and compared data to infections with the preceding Delta variant of concern (VOC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In a prospective, observational cohort study, healthy vaccinated UK adults who reported a positive polymerase chain reaction (PCR) or lateral flow test, self-swabbed on alternate weekdays until day 10. We compared participant-reported symptoms and viral load trajectories between infections caused by VOCs Delta and Omicron (sub-variants BA.1, BA.2 or BA.4\/5), and tested for relationships between vaccine dose, symptoms and PCR cycle threshold (Ct) as a proxy for viral load using Chi-squared (\u03c72) and Wilcoxon tests.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      563 infection episodes were reported among 491 participants. Across infection episodes, there was little variation in symptom burden (4 [IQR 3\u20135] symptoms) and duration (8 [IQR 6\u201311] days). Whilst symptom profiles differed among infections caused by Delta compared to Omicron sub-variants, symptom profiles were similar between Omicron sub-variants. Anosmia was reported more frequently in Delta infections after 2 doses compared with Omicron sub-variant infections after 3 doses, for example: 42% (25\/60) of participants with Delta infection compared to 9% (6\/67) with Omicron BA.4\/5 (\u03c7\n                      <jats:sup>2<\/jats:sup>\n                      P &lt; 0.001; OR 7.3 [95% CI 2.7\u201319.4]). Fever was less common with Delta (20\/60 participants; 33%) than Omicron BA.4\/5 (39\/67; 58%; \u03c7\n                      <jats:sup>2<\/jats:sup>\n                      P = 0.008; OR 0.4 [CI 0.2\u20130.7]). Amongst infections with an Omicron sub-variants, symptoms of coryza, fatigue, cough and myalgia predominated. Viral load trajectories and peaks did not differ between Delta, and Omicron, irrespective of symptom severity (including asymptomatic participants), VOC or vaccination status. PCR Ct values were negatively associated with time since vaccination in participants infected with BA.1 (\u03b2 = -0.05 (CI -0.10\u20130.01); P = 0.031); however, this trend was not observed in BA.2 or BA.4\/5 infections.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec004\">\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our study emphasises both the changing symptom profile of COVID-19 infections in the Omicron era, and ongoing transmission risk of Omicron sub-variants in vaccinated adults.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec005\">\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04750356\" xlink:type=\"simple\">NCT04750356<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pone.0294897","type":"journal-article","created":{"date-parts":[[2024,3,21]],"date-time":"2024-03-21T13:44:15Z","timestamp":1711028655000},"page":"e0294897","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":10,"title":["COVID-19 in non-hospitalised adults caused by either SARS-CoV-2 sub-variants Omicron BA.1, BA.2, BA.4\/5 or Delta associates with similar illness duration, symptom severity and viral kinetics, irrespective of vaccination history"],"prefix":"10.1371","volume":"19","author":[{"given":"Hermaleigh","family":"Townsley","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joshua","family":"Gahir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5610-6080","authenticated-orcid":true,"given":"Timothy W.","family":"Russell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Greenwood","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9343-4593","authenticated-orcid":true,"given":"Edward J.","family":"Carr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matala","family":"Dyke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8357-2327","authenticated-orcid":true,"given":"Lorin","family":"Adams","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Murad","family":"Miah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bobbi","family":"Clayton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9147-951X","authenticated-orcid":true,"given":"Callie","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5618-883X","authenticated-orcid":true,"given":"Mauro","family":"Miranda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harriet V.","family":"Mears","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chris","family":"Bailey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James R. M.","family":"Black","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashley S.","family":"Fowler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margaret","family":"Crawford","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9796-2040","authenticated-orcid":true,"given":"Katalin","family":"Wilkinson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew","family":"Hutchinson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruth","family":"Harvey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicola","family":"O\u2019Reilly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gavin","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Goldstone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rupert","family":"Beale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Padmasayee","family":"Papineni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tumena","family":"Corrah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Gilson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simon","family":"Caidan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2459-3480","authenticated-orcid":true,"given":"Jerome","family":"Nicod","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steve","family":"Gamblin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8457-2633","authenticated-orcid":true,"given":"George","family":"Kassiotis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincenzo","family":"Libri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bryan","family":"Williams","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonia","family":"Gandhi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam J.","family":"Kucharski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles","family":"Swanton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3052-0368","authenticated-orcid":true,"given":"David L. V.","family":"Bauer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2732-4497","authenticated-orcid":true,"given":"Emma C.","family":"Wall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2024,3,21]]},"reference":[{"key":"pone.0294897.ref001","author":"CfDCa Prevention","year":"2022","journal-title":"Ending Isolation and Precautions for People with COVID-19: Interim Guidance: CDC"},{"issue":"7897","key":"pone.0294897.ref002","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/s41586-021-04352-y","article-title":"Evolution of enhanced innate immune evasion by SARS-CoV-2","volume":"602","author":"LG Thorne","year":"2022","journal-title":"Nature"},{"key":"pone.0294897.ref003","first-page":"2021.12","article-title":"The altered entry pathway and antigenic distance of the SARS-CoV-2 Omicron variant map to separate domains of spike protein.","author":"TP Peacock","year":"2022","journal-title":"bioRxiv"},{"key":"pone.0294897.ref004","first-page":"2022.01.03","article-title":"The hyper-transmissible SARS-CoV-2 Omicron variant exhibits significant antigenic change, vaccine escape and a switch in cell entry mechanism.","author":"BJ Willett","year":"2022","journal-title":"medRxiv"},{"issue":"10292","key":"pone.0294897.ref005","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1016\/S0140-6736(21)01290-3","article-title":"Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination","volume":"397","author":"EC Wall","year":"2021","journal-title":"Lancet"},{"issue":"10296","key":"pone.0294897.ref006","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S0140-6736(21)01462-8","article-title":"AZD1222-induced neutralising antibody activity against SARS-CoV-2 Delta VOC","volume":"398","author":"EC Wall","year":"2021","journal-title":"Lancet"},{"issue":"10326","key":"pone.0294897.ref007","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/S0140-6736(22)00092-7","article-title":"Three-dose vaccination elicits neutralising antibodies against omicron","volume":"399","author":"M Wu","year":"2022","journal-title":"Lancet"},{"issue":"16","key":"pone.0294897.ref008","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1056\/NEJMoa2119451","article-title":"Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant.","volume":"386","author":"N Andrews","year":"2022","journal-title":"N Engl J Med"},{"issue":"7","key":"pone.0294897.ref009","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/S1473-3099(22)00154-2","article-title":"Risk of hospitalisation associated with infection with SARS-CoV-2 omicron variant versus delta variant in Denmark: an observational cohort study","volume":"22","author":"P Bager","year":"2022","journal-title":"Lancet Infect Dis"},{"issue":"9","key":"pone.0294897.ref010","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/S1473-3099(22)00320-6","article-title":"Global impact of the first year of COVID-19 vaccination: a mathematical modelling study","volume":"22","author":"OJ Watson","year":"2022","journal-title":"Lancet Infect Dis"},{"issue":"2","key":"pone.0294897.ref011","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S1473-3099(21)00648-4","article-title":"Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal, cohort study.","volume":"22","author":"A Singanayagam","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"pone.0294897.ref012","article-title":"Protection against symptomatic infection with delta (B.1.617.2) and omicron (B.1.1.529) BA.1 and BA.2 SARS-CoV-2 variants after previous infection and vaccination in adolescents in England, August, 2021-March, 2022: a national, observational, test-negative, case-control study.","author":"AA Powell","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"pone.0294897.ref013","author":"U. Government","year":"2022","journal-title":"Coronavirus dashboard"},{"issue":"3","key":"pone.0294897.ref014","article-title":"SARS-CoV-2 Omicron Symptomatic Infections in Previously Infected or Vaccinated South African Healthcare Workers","volume":"10","author":"MC Nunes","year":"2022","journal-title":"Vaccines (Basel)."},{"key":"pone.0294897.ref015","first-page":"2022.07.30","article-title":"Changes in COVID-19-related mortality across key demographic and clinical subgroups: an observational cohort study using the OpenSAFELY platform on 18 million adults in England.","author":"L Nab","year":"2022","journal-title":"medRxiv"},{"key":"pone.0294897.ref016","doi-asserted-by":"crossref","first-page":"e069676","DOI":"10.1136\/bmj-2021-069676","article-title":"Trajectory of long covid symptoms after covid-19 vaccination: community based cohort study","volume":"377","author":"D Ayoubkhani","year":"2022","journal-title":"BMJ"},{"issue":"10343","key":"pone.0294897.ref017","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1016\/S0140-6736(22)00941-2","article-title":"Risk of long COVID associated with delta versus omicron variants of SARS-CoV-2","volume":"399","author":"M Antonelli","year":"2022","journal-title":"Lancet"},{"issue":"1","key":"pone.0294897.ref018","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1038\/s41467-022-29521-z","article-title":"Persistent COVID-19 symptoms in a community study of 606,434 people in England.","volume":"13","author":"M Whitaker","year":"2022","journal-title":"Nature Communications"},{"issue":"10335","key":"pone.0294897.ref019","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1016\/S0140-6736(22)00327-0","article-title":"Symptom prevalence, duration, and risk of hospital admission in individuals infected with SARS-CoV-2 during periods of omicron and delta variant dominance: a prospective observational study from the ZOE COVID Study","volume":"399","author":"C Menni","year":"2022","journal-title":"Lancet"},{"issue":"6","key":"pone.0294897.ref020","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/S1473-3099(22)00069-X","article-title":"SARS-CoV-2 incidence, transmission, and reinfection in a rural and an urban setting: results of the PHIRST-C cohort study, South Africa, 2020\u201321","volume":"22","author":"C Cohen","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"pone.0294897.ref021","author":"NHS","year":"2022","journal-title":"COVID-19 when to self-isolate and what to do"},{"issue":"10395","key":"pone.0294897.ref022","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0140-6736(23)00917-0","article-title":"Independent SARS-CoV-2 staff testing protected academic and health-care institutions in northwest London","volume":"402","author":"C Bailey","year":"2023","journal-title":"The Lancet"},{"issue":"8","key":"pone.0294897.ref023","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1038\/s41587-020-0588-y","article-title":"Scalable and robust SARS-CoV-2 testing in an academic center","volume":"38","author":"J Aitken","year":"2020","journal-title":"Nat Biotechnol"},{"issue":"8","key":"pone.0294897.ref024","doi-asserted-by":"crossref","first-page":"e192","DOI":"10.1016\/S1473-3099(20)30483-7","article-title":"A minimal common outcome measure set for COVID-19 clinical research","volume":"20","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"pone.0294897.ref025","author":"U. Government","year":"2022","journal-title":"Guidance for people with symptoms of a respiratory viral infection including COVID-19: gov.uk"},{"key":"pone.0294897.ref026","volume-title":"R. A language and environment for statistical computing","year":"2022"},{"key":"pone.0294897.ref027","first-page":"2021.12","article-title":"The SARS-CoV-2 variant, Omicron, shows rapid replication in human primary nasal epithelial cultures and efficiently uses the endosomal route of entry.","author":"TP Peacock","year":"2022","journal-title":"bioRxiv."},{"issue":"5","key":"pone.0294897.ref028","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1038\/s41591-022-01780-9","article-title":"Safety, tolerability and viral kinetics during SARS-CoV-2 human challenge in young adults","volume":"28","author":"B Killingley","year":"2022","journal-title":"Nat Med"},{"key":"pone.0294897.ref029","article-title":"Duration of infectious shedding of SARS-CoV-2 Omicron variant and its relation with symptoms","author":"S Keske","year":"2022","journal-title":"Clin Microbiol Infect"},{"issue":"7","key":"pone.0294897.ref030","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1038\/s41591-022-01840-0","article-title":"Long COVID after breakthrough SARS-CoV-2 infection","volume":"28","author":"Z Al-Aly","year":"2022","journal-title":"Nature Medicine"},{"issue":"1","key":"pone.0294897.ref031","doi-asserted-by":"crossref","first-page":"6856","DOI":"10.1038\/s41467-022-34244-2","article-title":"Variant-specific symptoms of COVID-19 in a study of 1,542,510 adults in England.","volume":"13","author":"M Whitaker","year":"2022","journal-title":"Nature Communications"},{"key":"pone.0294897.ref032","article-title":"Associations of COVID-19 Symptoms with Omicron Subvariants BA.2 and BA.5, Host Status, and Clinical Outcomes: A Registry-Based Observational Study in Sapporo, Japan.","author":"S Nakakubo","year":"2023","journal-title":"medRxiv"},{"key":"pone.0294897.ref033","article-title":"High Asymptomatic Carriage with the Omicron Variant in South Africa","author":"N Garrett","year":"2022","journal-title":"Clin Infect Dis"},{"issue":"4","key":"pone.0294897.ref034","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1056\/NEJMoa2115481","article-title":"Duration of Protection against Mild and Severe Disease by Covid-19 Vaccines","volume":"386","author":"N Andrews","year":"2022","journal-title":"N Engl J Med"},{"key":"pone.0294897.ref035","doi-asserted-by":"crossref","first-page":"104402","DOI":"10.1016\/j.ebiom.2022.104402","article-title":"SARS-CoV-2-specific nasal IgA wanes 9 months after hospitalisation with COVID-19 and is not induced by subsequent vaccination.","volume":"87","author":"F Liew","year":"2023","journal-title":"EBioMedicine."},{"issue":"10","key":"pone.0294897.ref036","doi-asserted-by":"crossref","first-page":"e2235844","DOI":"10.1001\/jamanetworkopen.2022.35844","article-title":"COVID-19 Symptoms and Duration of Rapid Antigen Test Positivity at a Community Testing and Surveillance Site During Pre-Delta, Delta, and Omicron BA.1 Periods","volume":"5","author":"C Marquez","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"6","key":"pone.0294897.ref037","doi-asserted-by":"crossref","first-page":"e0027922","DOI":"10.1128\/msphere.00279-22","article-title":"Mucosal and Systemic Responses to Severe Acute Respiratory Syndrome Coronavirus 2 Vaccination Determined by Severity of Primary Infection.","volume":"7","author":"MM Sajadi","year":"2022","journal-title":"mSphere."},{"issue":"10319","key":"pone.0294897.ref038","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0140-6736(21)02754-9","article-title":"Two-dose ChAdOx1 nCoV-19 vaccine protection against COVID-19 hospital admissions and deaths over time: a retrospective, population-based cohort study in Scotland and Brazil.","volume":"399","author":"SV Katikireddi","year":"2022","journal-title":"Lancet"},{"key":"pone.0294897.ref039","first-page":"2022","article-title":"Transmission of SARS-CoV-2 Omicron VOC subvariants BA.1 and BA.2: Evidence from Danish Households.","author":"FP Lyngse","year":"2022","journal-title":"medRxiv"},{"issue":"3","key":"pone.0294897.ref040","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofad068","article-title":"Acceptability, Feasibility, and Validity of Detecting Respiratory Pathogens During Acute Respiratory Illness in Participant-Collected Swabs in a Low-Income, Community Sample.","volume":"10","author":"P Thind","year":"2023","journal-title":"Open Forum Infectious Diseases."},{"key":"pone.0294897.ref041","author":"J. Yapp R R","year":"2022","journal-title":"Coronavirus (COVID-19) Infection Survey, UK: 27 May 2022: ONS;"},{"issue":"9","key":"pone.0294897.ref042","doi-asserted-by":"crossref","first-page":"e2861","DOI":"10.1093\/cid\/ciaa1706","article-title":"Antigen-Based Testing but Not Real-Time Polymerase Chain Reaction Correlates With Severe Acute Respiratory Syndrome Coronavirus 2 Viral Culture","volume":"73","author":"A Pekosz","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"5","key":"pone.0294897.ref043","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1038\/s41564-022-01105-z","article-title":"Daily longitudinal sampling of SARS-CoV-2 infection reveals substantial heterogeneity in infectiousness.","volume":"7","author":"R Ke","year":"2022","journal-title":"Nat Microbiol."},{"key":"pone.0294897.ref044","first-page":"2022.01","article-title":"Viral dynamics and duration of PCR positivity of the SARS-CoV-2 Omicron variant.","author":"JA Hay","year":"2022","journal-title":"medRxiv"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0294897","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,21]],"date-time":"2024-03-21T13:44:43Z","timestamp":1711028683000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0294897"}},"subtitle":[],"editor":[{"given":"AbdulAzeez Adeyemi","family":"Anjorin","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2024,3,21]]},"references-count":44,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,3,21]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0294897","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2022.07.07.22277367","asserted-by":"object"}]},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,21]]}}}